[11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: Impact of epilepsy and drug-responsiveness

Nuclear Medicine and Biology

Volumn 40, Issue 6, 2013, Pages 764-775

  Syvänen, Stina ^a   Russmann, Vera ^b   Verbeek, Joost ^c   Eriksson, Jonas ^c,g   Labots, Maaike ^d   Zellinger, Christina ^b   Seeger, Natalie ^b   Schuit, Robert ^c   Rongen, Marissa ^c   van Kooij, Rolph ^c   Windhorst, Albert D ^c   Lammertsma, Adriaan A ^c   de Lange, Elizabeth C ^d   Voskuyl, Rob A ^d,e   Koepp, Matthias ^f   Potschka, Heidrun ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF MUNICH   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

^e STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

11C laniquidar; 11C quinidine; Epilepsy; P glycoprotein; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LANIQUIDAR C 11; MULTIDRUG RESISTANCE PROTEIN; PHENOBARBITAL; QUINIDINE C 11; RADIOPHARMACEUTICAL AGENT; TARIQUIDAR; UNCLASSIFIED DRUG; BENZAZEPINE DERIVATIVE; CARBON; LANIQUIDAR; QUINIDINE; QUINOLINE DERIVATIVE; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG METABOLISM; DRUG RESPONSE; DRUG STABILITY; DRUG SYNTHESIS; DRUG UPTAKE; ELECTRODE; ELECTROENCEPHALOGRAM; EPILEPSY; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MORNING DOSAGE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; RAT; SEIZURE; TRANSPORT KINETICS; ANIMAL; BLOOD; CHEMISTRY; CHRONIC DISEASE; DIAGNOSTIC USE; DISEASE MODEL; GENE EXPRESSION REGULATION; KINETICS; METABOLISM; PROCEDURES; RADIOCHEMISTRY; RECURRENT DISEASE; SCINTISCANNING; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; [(11)C]LANIQUIDAR; [(11)C]QUINIDINE; METHODOLOGY;

ANIMALS; BENZAZEPINES; CARBON RADIOISOTOPES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; EPILEPSY; FEMALE; GENE EXPRESSION REGULATION; KINETICS; MALE; P-GLYCOPROTEIN; PHENOBARBITAL; POSITRON-EMISSION TOMOGRAPHY; QUINIDINE; QUINOLINES; RADIOCHEMISTRY; RATS; RATS, SPRAGUE-DAWLEY; RECURRENCE; TREATMENT OUTCOME;

[(11)C]LANIQUIDAR; [(11)C]QUINIDINE; EPILEPSY; P-GLYCOPROTEIN; POSITRON EMISSION TOMOGRAPHY;

EID: 84881028019     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.05.008     Document Type: Article

References (47)

1. Loscher W., Luna-Tortos C., Romermann K., Fedrowitz M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr Pharm Des 2011, 17:2808-2828.
2. Potschka H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies?. Epilepsia 2010, 51:1333-1347.
3. Kwan P., Li H.M., Al-Jufairi E., Abdulla R., Gonzales M., Kaye A.H., et al. Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol Dis 2010, 39:192-197.
4. 11C]verapamil measured with PET. Neuroimage 2003, 20:1775-1782.
5. Hendrikse N.H., de Vries E.G., Eriks-Fluks L., van der Graaf W.T., Hospers G.A., Willemsen A.T., et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 1999, 59:2411-2416.
6. Sasongko L., Link J.M., Muzi M., Mankoff D.A., Yang X., Collier A.C., et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005, 77:503-514.
7. Syvänen S., Blomquist G., Sprycha M., Hoglund A.U., Roman M., Eriksson O., et al. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage 2006, 32:1134-1141.
8. Seneca N., Zoghbi S.S., Liow J.S., Kreisl W., Herscovitch P., Jenko K., et al. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. J Nucl Med 2009, 50:807-813.
9. Lazarova N., Zoghbi S.S., Hong J., Seneca N., Tuan E., Gladding R.L., et al. Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem 2008, 51:6034-6043.
10. Syvänen S., Hammarlund-Udenaes M. Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. Curr Top Med Chem 2010, 10:1799-1809.
11. Volk H.A., Loscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. Brain 2005, 128:1358-1368.
12. 11C-labelled quinidine and tamoxifen. J Labelled Compd Radiopharm 1985, 22:535-545.
13. Windhorst A.D., ter Linden T., de Nooij A., Buijs F.L., van Rooij L.F., Hersheid J.D.M. A complete multipurpose, low cost, fully automated and GMP compliant radiosynthesis system. J Labelled Compd Radiopharm 2001, 44:S1052.
14. Jewett D.M. A simple synthesis of [11C]methyl triflate. Int J Rad Appl Instrum A 1992, 43:1383-1385.
15. Luurtsema G., Schuit R.C., Klok R.P., Verbeek J., Leysen J.E., Lammertsma A.A., et al. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol 2009, 36:643-649.
16. Pekcec A., Fuest C., Muhlenhoff M., Gerardy-Schahn R., Potschka H. Targeting epileptogenesis-associated induction of neurogenesis by enzymatic depolysialylation of NCAM counteracts spatial learning dysfunction but fails to impact epilepsy development. J Neurochem 2008, 105:389-400.
17. Brandt C., Gastens A.M., Sun M., Hausknecht M., Loscher W. Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 2006, 51:789-804.
18. Brandt C., Glien M., Potschka H., Volk H., Loscher W. Epileptogenesis and neuropathology after different types of status epilepticus induced by prolonged electrical stimulation of the basolateral amygdala in rats. Epilepsy Res 2003, 55:83-103.
19. Racine R., Okujava V., Chipashvili S. Modification of seizure activity by electrical stimulation. 3. Mechanisms. Electroencephalogr Clin Neurophysiol 1972, 32:295-299.
20. Schlichtiger J., Pekcec A., Bartmann H., Winter P., Fuest C., Soerensen J., et al. Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy. Br J Pharmacol 2010, 160:1062-1071.
21. Bartmann H., Fuest C., la Fougere C., Xiong G., Just T., Schlichtiger J., et al. Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia 2010, 51:1780-1790.
22. de Jong H.W., van Velden F.H., Kloet R.W., Buijs F.L., Boellaard R., Lammertsma A.A. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol 2007, 52:1505-1526.
23. van Velden F.H., Kloet R.W., van Berckel B.N., Molthoff C.F., de Jong H.W., Lammertsma A.A., et al. Impact of attenuation correction strategies on the quantification of High Resolution Research Tomograph PET studies. Phys Med Biol 2008, 53:99-118.
24. van Velden F.H., Kloet R.W., van Berckel B.N., Buijs F.L., Luurtsema G., Lammertsma A.A., et al. HRRT versus HR+human brain PET studies: an interscanner test-retest study. J Nucl Med 2009, 50:693-702.
25. Loening A.M., Gambhir S.S. AMIDE: A free software tool for multimodality medical image analysis. Mol Imaging 2003, 2:131-137.
26. Buiter H.J., van Velden F.H., Leysen J.E., Fisher A., Windhorst A.D., Lammertsma A.A., et al. Reproducible Analysis of Rat Brain PET Studies Using an Additional [(18)F]NaF Scan and an MR-Based ROI Template. Int J Mol Imaging 2012, 580717:1-10.
27. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990, 10:740-747.
28. Pekcec A., Unkruer B., Schlichtiger J., Soerensen J., Hartz A.M., Bauer B., et al. Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J Pharmacol Exp Ther 2009, 330:939-947.
29. Zibell G., Unkruer B., Pekcec A., Hartz A.M., Bauer B., Miller D.S., et al. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009, 56:849-855.
30. Volk H.A., Burkhardt K., Potschka H., Chen J., Becker A., Loscher W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004, 123:751-759.
31. Volk H.A., Potschka H., Loscher W. Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 2004, 58:67-79.
32. Volk H., Potschka H., Loscher W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 2005, 53:517-531.
33. Mairinger S., Erker T., Muller M., Langer O. PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab 2011, 12:774-792.
34. Syvänen S., Eriksson J. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem Neurosci. 2013, 4:225-237.
35. Patil A.G., D'Souza R., Dixit N., Damre A. Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer. Eur J Drug Metab Pharmacokinet 2011, 36:115-119.
36. Horio M., Gottesman M.M., Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci U S A 1988, 85:3580-3584.
37. Syvänen S., Schenke M., van den Berg D.J., Voskuyl R.A., de Lange E.C. Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-a study in rats subjected to status epilepticus by kainate. AAPS J 2012, 14:87-96.
38. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10:159-165.
39. Colabufo N.A., Berardi F., Perrone M.G., Capparelli E., Cantore M., Inglese C., et al. Substrates, inhibitors and activators of P-glycoprotein: candidates for radiolabeling and imaging perspectives. Curr Top Med Chem 2010, 10:1703-1714.
40. Bauer F., Kuntner C., Bankstahl J.P., Wanek T., Bankstahl M., Stanek J., et al. Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg 2010, 18:5489-5497.
41. Dörner B., Kuntner C., Bankstahl J.P., Bankstahl M., Stanek J., Wanek T., et al. Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem 2009, 52:6073-6082.
42. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009, 323:1718-1722.
43. Sharom F.J. The P-glycoprotein multidrug transporter. Essays Biochem 2011, 50:161-178.
44. Akiyama S., Cornwell M.M., Kuwano M., Pastan I., Gottesman M.M. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 1988, 33:144-147.
45. Jette L., Murphy G.F., Leclerc J.M., Beliveau R. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol 1995, 50:1701-1709.
46. Heinemann U., Kaufer D., Friedman A. Blood-brain barrier dysfunction, TGFbeta signaling, and astrocyte dysfunction in epilepsy. Glia 2012, 60:1251-1257.
47. van Vliet E.A., van Schaik R., Edelbroek P.M., Voskuyl R.A., Redeker S., Aronica E., et al. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats. J Pharmacol Exp Ther 2007, 322:141-147.